Anshel Bright
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Researcher
Also affiliated: United States Food and Drug Administration (2022–2023)
Graduate Student Researcher
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Anshel Bright's research investigates the efficacy of nanocrystal formulations for poorly soluble drugs. Their work has focused on evaluating the immune response and risk assessment associated with Zileuton, a BCS-II drug, when formulated as nanocrystals and administered orally. Studies have utilized Sprague Dawley rats to assess mucosal immune profiles, including cytokine levels, and to conduct in vivo risk assessments. Bright has co-authored two publications in this area, collaborating with researchers from the National Center for Toxicological Research, including Sangeeta Khare and Kuppan Gokulan.
Metrics
- h-index: 1
- Publications: 2
- Citations: 5
Selected Publications
-
Evaluation of mucosal immune profile associated with Zileuton nanocrystal-formulated BCS-II drug upon oral administration in Sprague Dawley rats (2023)
Collaboration Network
Top Collaborators
- Evaluation of mucosal immune profile associated with Zileuton nanocrystal-formulated BCS-II drug upon oral administration in Sprague Dawley rats
- Evaluation of mucosal immune profile associated with Zileuton nanocrystal-formulated BCS-II drug upon oral administration in Sprague Dawley rats
- Evaluation of mucosal immune profile associated with Zileuton nanocrystal-formulated BCS-II drug upon oral administration in Sprague Dawley rats
- Evaluation of mucosal immune profile associated with Zileuton nanocrystal-formulated BCS-II drug upon oral administration in Sprague Dawley rats
- Evaluation of mucosal immune profile associated with Zileuton nanocrystal-formulated BCS-II drug upon oral administration in Sprague Dawley rats
Similar Researchers
Based on overlapping research topics